Pancreatic Cancer Trial Landscape (November 2026)

Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

678
Recruiting
229
Phase 1
314
Phase 2
64
Phase 3
8
Phase 4

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Looking for pancreatic cancer trials matched to your specific case?

Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.

Find My Matches →

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Chemotherapy
79
Other / unclassified
53
Checkpoint inhibitor
51
Antibody-drug conjugate (ADC)
24
Monoclonal antibody
19
Small-molecule inhibitor
18
Other inhibitor
18
Bispecific antibody
17
CAR-T cellular therapy
16
Vaccine (other)
10
mRNA / neoantigen vaccine
8
Covalent small-molecule inhibitor
5

Recently Updated Trials

NCTPhaseTitleMechanism
NCT05321316—Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid TumorsNectin-4 -- imaging probe for PET detection of nectin-4 expression (radiotracer)
NCT048583342APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPARP inhibition (Olaparib)
NCT067528113Polymeric Micellar Paclitaxel for Metastatic Pancreatic CancerPolymeric micellar paclitaxel + gemcitabine chemotherapy
NCT07873606—Histotripsy x Pancreatic CancerUnknown mechanism
NCT079457821, 2A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic CancerPD-1 (via toripalimab/ iparomlimab) -- immune checkpoint blockade (monoclonal antibody) combined with DNA-damaging chemotherapy (gemcitabine) and radiotherapy (multimodal therapy)

Top Sponsors

SponsorRecruiting trials
Fudan University20
Tianjin Medical University Cancer Institute and Hospital18
Ruijin Hospital14
Zhejiang University12
Minia University9

Geographic Distribution

Countries/regions with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country/region.

United States
232
China
221
France
49
Spain
36
Italy
32
South Korea
29
Canada
27
United Kingdom
24
Japan
24
Netherlands
18

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

StartNCTTitleMechanism
Jun 1, 2027NCT07619521Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaMEK1/2 + HER2 -- MEK inhibitor + antibody-drug conjugate (ADC)
Apr 13, 2027NCT07898813Daraxonrasib in Resectable PDACKRAS -- covalent inhibitor (small molecule)
Jan 15, 2027NCT07905131A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic CancerEZH2 -- methyltransferase inhibitor (epigenetic modulator)
Dec 16, 2026NCT0760862764Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic CancerPSCA -- radiolabeled antibody fragment for imaging (radioconjugate)
Dec 1, 2026NCT07645651Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic CancerCDK7 -- kinase inhibitor (small molecule)
Dec 1, 2026NCT07945782A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic CancerPD-1 (via toripalimab/ iparomlimab) -- immune checkpoint blockade (monoclonal antibody) combined with DNA-damaging chemotherapy (gemcitabine) and radiotherapy (multimodal therapy)
Dec 2026NCT07444541ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic CancerCLDN18.2 -- monoclonal antibody
Dec 2026NCT07594067TCR1188-ABC Cells in KRAS-mutated CancersKRAS mutant peptides -- T cell receptor (TCR) engineered T cells

You've seen the pancreatic cancer landscape. Now find the trials that fit your case.

Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.

Find My Matches →

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.